Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biogen Inc. stock logo
BIIB
Biogen
$128.39
+2.1%
$124.04
$110.04
$238.00
$18.81B0.121.39 million shs1.58 million shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$122.64
+2.0%
$108.59
$84.23
$157.98
$12.14B0.261.13 million shs1.28 million shs
Repligen Co. stock logo
RGEN
Repligen
$122.54
+3.7%
$129.41
$102.97
$182.52
$6.88B1.21740,435 shs630,733 shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shs86 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biogen Inc. stock logo
BIIB
Biogen
+2.05%-1.65%+8.04%-8.62%-41.05%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
+2.05%-0.26%+14.91%+4.29%-12.02%
Repligen Co. stock logo
RGEN
Repligen
+3.72%-3.96%-15.34%-24.73%-22.52%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biogen Inc. stock logo
BIIB
Biogen
4.9106 of 5 stars
4.25.00.03.73.52.51.9
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.9351 of 5 stars
4.43.00.02.93.62.53.1
Repligen Co. stock logo
RGEN
Repligen
4.8373 of 5 stars
4.31.00.04.54.03.31.9
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biogen Inc. stock logo
BIIB
Biogen
2.38
Hold$191.3049.00% Upside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.86
Moderate Buy$162.0032.09% Upside
Repligen Co. stock logo
RGEN
Repligen
2.64
Moderate Buy$173.2541.38% Upside
Seagen Inc. stock logo
SGEN
Seagen
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SGEN, RGEN, NBIX, and BIIB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/7/2025
Biogen Inc. stock logo
BIIB
Biogen
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$207.00 ➝ $169.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$137.00 ➝ $145.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$160.00 ➝ $154.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$137.00 ➝ $152.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Perform ➝ Market Perform$96.00 ➝ $115.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$155.00 ➝ $165.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$138.00 ➝ $139.00
5/6/2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$158.00 ➝ $160.00
5/5/2025
Biogen Inc. stock logo
BIIB
Biogen
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$185.00 ➝ $175.00
5/5/2025
Repligen Co. stock logo
RGEN
Repligen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biogen Inc. stock logo
BIIB
Biogen
$9.82B1.92$21.08 per share6.09$114.71 per share1.12
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.41B5.03$3.57 per share34.35$25.97 per share4.72
Repligen Co. stock logo
RGEN
Repligen
$650.43M10.58$2.29 per share53.61$35.19 per share3.48
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biogen Inc. stock logo
BIIB
Biogen
$1.63B$10.1311.477.781.5116.87%14.98%8.76%8/7/2025 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$341.30M$2.9537.2818.960.7714.49%13.38%9.73%8/7/2025 (Estimated)
Repligen Co. stock logo
RGEN
Repligen
$35.60M-$0.45N/A51.924.54-4.64%4.21%2.94%7/29/2025 (Estimated)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A

Latest SGEN, RGEN, NBIX, and BIIB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2025Q1 2025
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$0.70$0.08-$0.62$0.08$587.06 million$572.60 million
5/1/2025Q1 2025
Biogen Inc. stock logo
BIIB
Biogen
$3.26$3.02-$0.24$1.64$2.25 billion$2.43 billion
4/29/2025Q1 2025
Repligen Co. stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
Repligen Co. stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biogen Inc. stock logo
BIIB
Biogen
0.27
1.35
0.90
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
3.40
3.28
Repligen Co. stock logo
RGEN
Repligen
0.26
10.44
8.76
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12

Institutional Ownership

CompanyInstitutional Ownership
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
Repligen Co. stock logo
RGEN
Repligen
97.64%
Seagen Inc. stock logo
SGEN
Seagen
84.26%

Insider Ownership

CompanyInsider Ownership
Biogen Inc. stock logo
BIIB
Biogen
0.16%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.80%
Repligen Co. stock logo
RGEN
Repligen
1.20%
Seagen Inc. stock logo
SGEN
Seagen
25.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biogen Inc. stock logo
BIIB
Biogen
8,720146.53 million146.14 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
1,20098.97 million95.42 millionOptionable
Repligen Co. stock logo
RGEN
Repligen
2,02056.18 million55.36 millionOptionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionOptionable

Recent News About These Companies

Seagen posts breast cancer win ahead of Pfizer takeover
Is Merck planning a $30bn-plus move for Seagen?
Franklin Biotechnology Discovery C
Pfizer: Turning The Corner (Rating Upgrade)
MRNA Feb 2024 64.000 put
MRNA Feb 2024 77.000 call
MRNA Feb 2024 67.000 put

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biogen stock logo

Biogen NASDAQ:BIIB

$128.39 +2.58 (+2.05%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$128.60 +0.21 (+0.16%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$122.64 +2.46 (+2.05%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$124.50 +1.86 (+1.52%)
As of 08:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Repligen stock logo

Repligen NASDAQ:RGEN

$122.54 +4.39 (+3.72%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$122.49 -0.05 (-0.04%)
As of 05/27/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Seagen stock logo

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.